Definium Therapeutics, Inc. (NASDAQ:DFTX) Stock Has Average Price Target of $66.00 According to Brokerages

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have earned an average recommendation of “Moderate Buy” from the twenty-one ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, nineteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $66.00.

A number of analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and set a $66.00 price target on shares of Definium Therapeutics in a research report on Monday, September 14th. UBS Group restated a “buy” rating and set a $70.00 price objective on shares of Definium Therapeutics in a research report on Tuesday, September 15th. JonesTrading boosted their price objective on Definium Therapeutics from $74.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Robert W. Baird upped their price objective on Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 15th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, October 19th.

Insider Buying and Selling

In other news, CFO Brandi Roberts sold 3,377 shares of the company’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $123,496.89. Following the completion of the transaction, the chief financial officer owned 394,528 shares in the company, valued at approximately $14,427,888.96. This represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Sullivan sold 14,051 shares of the stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $513,845.07. Following the completion of the sale, the insider directly owned 494,228 shares in the company, valued at approximately $18,073,917.96. This trade represents a 2.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 71,098 shares of company stock valued at $2,626,115. 2.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DFTX. Wellington Management Group LLP bought a new stake in shares of Definium Therapeutics in the second quarter valued at about $138,755,000. Seven Fleet Capital Management LP acquired a new stake in Definium Therapeutics during the second quarter worth about $6,992,000. TD Waterhouse Canada Inc. acquired a new stake in Definium Therapeutics during the second quarter worth about $1,592,000. Arizona State Retirement System bought a new position in Definium Therapeutics during the second quarter valued at about $1,431,000. Finally, Stableford Capital II LLC acquired a new position in Definium Therapeutics in the 2nd quarter valued at approximately $1,277,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Stock Performance

Shares of NASDAQ DFTX opened at $35.67 on Thursday. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm’s 50-day moving average price is $38.48 and its two-hundred day moving average price is $34.07. Definium Therapeutics has a 52-week low of $10.46 and a 52-week high of $49.70. The stock has a market capitalization of $4.79 billion, a P/E ratio of -10.40 and a beta of 2.19.

Definium Therapeutics (NASDAQ:DFTX) last issued its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, sell-side analysts forecast that Definium Therapeutics will post -3.08 earnings per share for the current year.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.